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Abstract
Background—Our previous study indicated that gene expression profiling of intestinal
metaplasia (IM) or spasmolytic polypeptide-expressing metaplasia (SPEM) can identify useful
prognostic markers of early stage gastric cancer, and seven metaplasia biomarkers (MUC13,
CDH17, OLFM4, KRT20, LGALS4, MUC5AC, and REG4) were selectively expressed in
17-50% of gastric cancer tissues. We investigated whether the combined expression of these
metaplasia biomarkers could predict the prognosis of advanced stage gastric cancer.
Methods—The expression of seven metaplasia biomarkers was evaluated
immunohistochemically using tissue microarrays comprised of 450 gastric cancer patients. The
clinicopathologic correlations and the prognostic impact were analyzed according to the
expression of multiple biomarkers.
Results—MUC13, CDH17, LGALS4 and REG4 were significant prognostic biomarkers in
univariate analysis. No expression of four markers was found in 56 cases (14.2%); 1 marker was
seen in 67 cases (17.0%), 2 in 106 cases (27.0%), 3 in 101 cases (25.7%), and 4 in 63 cases
(16.0%). Patients in which ≤ 2 proteins were expressed (Group B) showed younger age,
undifferentiated or diffuse type cancer, a larger tumor size, a larger number of metastatic lymph
nodes and more advanced stage than those in which ≥ 3 proteins were expressed (Group A). In
undifferentiated or stage II/III gastric cancer, the prognosis of Group B was significantly poorer
than that of Group A by multivariate analysis.
Conclusion—The combined loss of expression of multiple metaplasia biomarkers is considered
as an independent prognostic indicator in undifferentiated or stage II/III gastric cancer.
Introduction
Multiple gene expression profiling using cDNA microarrays and/or tissue arrays has been
widely used for the prediction of prognosis in breast cancer, lung cancer, lymphoma and
colon cancer.[1-4] While the application of cDNA microarrays allows for the precise
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analysis of the expression pattern of many suspected genes in each tissue, tissue microarray
technology can accelerate the complex tissue analysis of genes with clinicopathologic
findings, such as diagnostic or prognostic data.[5-7]
Recently several studies have reported useful biomarkers which might be related to gastric
cancer as well as premalignant gastric lesions.[8, 9] Compared with the cancer tissue, which
often shows heterogenous cell morphologies, the metaplastic lineages are often more
uniform, even compared with the lineages from the normal stomach.[10] We have
previously reported gene microarray studies analyzing laser capture-microdissected samples
of both intestinal metaplasia (IM) and spasmolytic polypeptide-expressing metaplasia
(SPEM) in humans as well as SPEM in mice.[11, 12] Using this approach, we also reported
that CDH17, which was selectively expressed in both IM or SPEM, is a single, independent
metaplasia biomarker for the prediction of prognosis in stage I or node-negative gastric
cancer.[11]
The utility of single biomarker for cancer detection or prognosis has often been fraught with
difficulties due to various interfering conditions.[8, 13-15] Nevertheless, several studies
have employed multiple genes or proteins as useful biomarkers for tumor progression as
well as cancer prediction.[16, 17] However, few previous investigations have evaluated how
markers of metaplasia could reflect prognosis in gastric cancer with advanced stages. In our
previous studies about biomarkers of metaplasia, we found that seven proteins selectively
expressed in either IM or SPEM including MUC13, CDH17, OLFM4, KRT20, LGALS4,
MUC5AC and REG4 were also expressed in 17-50% of human gastric cancer tissues
compared with normal gastric mucosa.[11]
The purpose of this study was to analyze the expression profiles of multiple proteins
selectively expressed in IM and/or SPEM as well as gastric cancer, and to investigate the
prognostic impact of the combination of protein biomarkers in advanced stage gastric
cancer.
Methods
To identify the expression profiles of seven metaplasia biomarkers, MUC13, CDH17,
OLFM4, KRT20, LGALS4, MUC5AC and REG4, which were found from the previous
study, immunostaining was performed on tissue microarray (TMAs) comprised of 450
gastric adenocarcinomas resected at Seoul National University Hospital in 2004
(SNUH-2004-GC; SuperBioChips. During the operation, D2 lymph node dissection was
performed on the patients who underwent curative resection, irrespective of the type of
gastrectomy.[18] None of the patients received neoadjuvant chemotherapy or radiation
therapy before the surgery. Adjuvant chemotherapy, most commonly a 5-fluorouracil-based
combination was usually indicated in patients with stage II or higher stages.
In addition to the 3 proteins (CDH17, MUC13 and OLFM4) which were evaluated in our
previous study, we performed immunohistochemical staining for an additional four proteins
(MUC5AC, KRT20, LGALS4 and REG4) with commercially available antibodies.[11]
TMAs were assembled according to the following procedure: Core tissue biopsies (diameter
2 mm) were obtained from individual paraffin-embedded gastric tumors (donor blocks) and
arranged in new recipient paraffin blocks (tissue array blocks) using a trephine apparatus
(Superbiochips Laboratories, Seoul, Korea). The tissue array blocks contained up to 60 cores
on 8 arrays, for a total of 450 cases for immunohistochemistry (IHC) staining. Tumors
occupying more than 10% of the core area were considered adequate. Each paraffin block
contained internal controls, which consisted of non-neoplastic gastric mucosa from the body
and antrum as well as intestinal metaplasia. IHC was performed using a Leica Bond-max
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automated immunostainer (Leica Microsystems, Newcastle, UK), as described by the
manufacturer's protocol.
After tissues were sampled from in each core, staining patterns were scored as 0 (negative),
1 (weakly to moderately positive) and 2 (strongly positive), which was separated into
negative (0) and positive (1 or 2) groups. For statistical analysis, cellular staining was
considered positive only when more than 10% of the total cancer cells within 1 core were
stained. The immunohistochemical staining for each core was assessed and scored without
any clinical information.
The clinicopathologic and prognostic significance of the expression of these proteins was
analyzed using SNUH-2004-GC TMA for the following variables: age, sex, the WHO
differentiation, the Lauren classification, tumor size, the number of metastatic lymph nodes
and retrieved lymph nodes, lymphatic/ venous/ perineural invasion, TNM stage, radicality
and disease-specific survival.[19] Regarding the WHO differentiation, papillary, well
differentiated and moderately differentiated types were categorized as the differentiated
group, and poorly differentiated, signet ring cell and mucinous types were categorized as the
undifferentiated group.
The correlations between multiple protein staining results and clinicopathologic
characteristics were analyzed. The Student's t test and chi-square test were used for
comparative statistical analyses. Disease- specific survival rates were evaluated by the
Kaplan-Meier method and the prognoses were compared using the log-rank test. All
clinicopathologic variables as well as the expression of the combination of multiple protein
biomarkers with a log-rank P value less than 0.05 were entered into the multivariate
analysis. The Cox proportional hazards model was used for the multivariate analysis to
identify independent prognostic factors. All tests were 2-sided and were performed at the
5% level of significance using SPSS version 17.0 (SPSS Inc, Chicago, IL, USA). The
median follow-up period was 49.1 months (range, 0.4-64.4 months).
This study was approved by the Institutional Review Board of Seoul National University
Hospital (H-1102-062-351).
Results
Table 2 shows the demographic data for the patients samples on the SNUH-2004-GC tissue
microarray, including age, sex, tumor location, tumor size, the number of metastatic lymph
nodes, the number of retrieved lymph nodes, the Lauren classification, the WHO
classification, lymphatic/venous/perineural invasion and TNM stage. The staining patterns
of MUC13, CDH17, OLFM4, KRT20, LGALS4, MUC5AC and REG4 in the SNUH-2004-
GC TMA are shown in Fig. 1.
Among the biomarkers tested, MUC13 showed two distinct expression patterns: one is the
membranous type which is usually expressed in intestinal type tumors (MUC13m), and the
other is the diffuse cytoplasmic type (MUC13c) as previously described.[11]
Among the seven proteins, four markers including MUC13m, CDH17, REG4 and LGALS4,
were significantly related to the prognosis of gastric cancer by univariate survival analysis,
whereas MUC13c, OLFM4, KRT20 and MUC5AC were not significantly related to survival
rates (Fig. 2) The correlations between the expression profiles and clinicopathologic
parameters of former four protein markers were analyzed (Table 3). The loss of CDH17
expression was more frequently associated with undifferentiated type and diffuse type
cancer . The loss of REG4 expression showed significant association with younger age,
diffuse type cancer, perineural invasion, advanced T stage and M1 stage. The loss of
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LGALS4 expression was significantly associated with lymphatic invasion, N stage and M
stage. All clinicopathologic variables except for lymphatic or venous invasion were
significantly associated with MUC13m expression
The combined expression of CDH17, REG4, LGALS4 and MUC13m was divided into five
groups according to expression patterns. No expression of the four protein markers was
found in 56 cases (14.2%); one marker was seen in 67 cases (17.0%), two in 106 cases
(27.0%), three in 101 cases (25.7%), and four in 63 cases (16.0%). Among CDH17, REG4
and LGALS4 and MUC13m, the combined expression of 3 or 4 protein biomarkers was
classified as the positive expression group (Group A) and that of 2 or fewer protein markers
was classified as the expression loss group (Group B). Group B showed a younger age
population, undifferentiated and diffuse type tumors, larger tumor size, a larger number of
metastatic lymph nodes, more frequent lymphatic/perineural invasion, less frequent R0
resection and more advanced stage (Table 4). Regarding disease-specific survival analysis,
the combined expression loss of protein biomarkers was significantly correlated with the
prognosis, and Group B showed a significantly poorer survival rate than Group A (Fig. 3).
By subgroup analysis, Group B showed a significantly poorer prognosis than Group A for
undifferentiated cancer, ≥ T2 advanced gastric cancer (AGC), and node-positive (N+) as
well as node-negative cancer (Fig. 4). For TNM stage, even though there was no significant
difference between the two groups in both stage I and stage IV cancers, Group B showed a
significantly poorer prognosis than Group A in stages II/III (Fig. 5). In multivariate analysis,
the combined loss of expression for MUC13m, CDH17, REG4 and LGALS4 proved to be
an independent prognostic factor in undifferentiated cancer, AGC, N+ cancer and stage II/III
cancer (Table 5).
Discussion
The current study revealed that the profiling of the combined expression of four metaplasia
biomarkers could be used as an independent prognostic marker in undifferentiated type
gastric cancer or in AGC. Little is known about the genetic pathway or the mechanism for
carcinogenesis or tumor progression in undifferentiated gastric cancer, especially compared
with that of differentiated gastric cancer.[20, 21] During tumor progression, gastric
adenocarcinomas tend to lose differentiation markers present in metaplasia, leading to less
differentiated phenotypes.[14] Other investigations have also suggested that the predominant
histologic type may be altered from the differentiated to the undifferentiated type with
increasing tumor size and the progression of the tumor.[22, 23] Certain undifferentiated-type
carcinomas may derive from the differentiated type tumors through progressive loss of cell-
to-cell adhesion by the loss of cell-adhesion molecules.[14] The results of these previous
reports and our present findings suggest that the cumulative loss of the expression of
differentiation-related proteins during the progression of the tumor may cause differentiated
gastric cancer to evolve into the undifferentiated type, resulting in a poorer prognosis.
The proteins biomarkers utilized in our investigations have similar functions related to cell
to cell adhesion or differentiation. CDH17 (cadherin-17, liver-intestine cadherin) is a
member of the cadherin family and works as a functional calcium-dependent cell adhesion
molecule.[11, 24] We have previously reported that CDH 17 is a promising prognostic
marker for early stage gastric cancer.[11]
The human MUC13 gene encodes an epithelial and hemopoietic transmembrane mucin, and
it is most highly expressed in epithelial tissues, especially those of the gastrointestinal and
respiratory tracts.[25] In gastric cancer, MUC13 is a good differentiation marker for the
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gastrointestinal mucosa and has distinct roles in the carcinogenesis of diffuse type gastric
cancer.[26]
LGALS4, a novel biomarker for gastric cancer, belongs to a subfamily of galectins which is
composed of two carbohydrate recognition domains within the same peptide and is involved
in a number of biological steps including cell to cell adhesion, growth regulation and
signaling pathways.[27, 28] Within human epithelial cancer cell lines, LGALS4 is
overexpressed in highly differentiated cell lines, but is absent in less differentiated lines.[28]
Balan et al. also reported LGALS4 as a useful tumor marker for gastric cancer progression
and the potential for lymph node metastasis[29] Based on these previous studies and the
results of our study, it appears that LGALS4 is expressed in more differentiated cancers,
particularly Group A patients in our study, and loss of protein expression is associated with
tumor progression or dedifferentiation in Group B patients.
The regenerating gene (REG) was originally isolated from regenerating rat pancreatic islets
and is a trophic factor for both islet cells and gastric epithelial cells.[30, 31] Human REG4 is
expressed in gastrointestinal cancers, pancreas cancer and carcinoid tumors, and it is
associated with intestinal metaplasia or increased cellular differentiation in the gastric
cancer.[32] The biological function of REG4 is poorly understood. REG4 has been known to
enhances peritoneal metastasis in gastric cancer or to be involved in apoptosis resistance
because of its 5-FU resistance.[15, 33] On the other hand REG4 expression has often been
considered as a good differentiation biomarker for gastric precancerous lesions.[32] These
results suggest that REG4 may promote differentiation in metaplasia while enhancing
carcinogenesis or tumor progression in gastric cancer with more advanced stage, which
highlights the difficulties of using a single marker in prognostic studies.
In this study, we found that the cumulative expression of cell-to-cell adhesion or
differentiation related proteins is an independent prognostic factor in not only
undifferentiated gastric cancer but also AGC or N+ gastric cancer. Cell-to-cell adhesion
molecule expression may be influenced by maturation as well as malignant transformation
of cells, and down-regulation of cell adhesion molecules may be a common event in the
carcinogenesis of gastric cancer.[34, 35] Previous studies have demonstrated that the loss of
cell adhesion molecule expression was significantly related to the loss of contact inhibition
of growth, cellular dedifferentiation and the disorganization of tissue architecture, and is
potentially important in the formation of metastases from adenocarcinoma.[35-38]. In
addition to the proteins assessed in our study, a number of cell-adhesion proteins, including
E-cadherin, dysadherin, CD44 focal adhesion kinase, syndecan-1 and integrins, have been
associated with the prognosis of gastric cancer.[17, 37, 39-41] Unlike these previous studies,
we have postulated that the cumulative loss of expression of adhesion or differentiation
protein biomarkers, which were selectively expressed in premalignant metaplasia, could
induce the disorganization of tissue architecture as well as cellular dedifferentiation, elevate
the invasive potential into adjacent tissue including lymphatics, and influence the behavior
of AGC or N+ cancer.
In the present study, protein expressions in each gastric cancer case are based on the
immunohistochemical analysis of one core on TMAs. In terms of the possible diversity of
histological components or molecular abnormality of advanced gastric cancer, we have
already shown excellent agreement in the staining results of the different intratumoral areas
of gastric carcinomas including advanced gastric cancer, and the effects of intratumoral
heterogeneity can be averaged out in such a large scale analysis as our study.[7, 42, 43]
Unfortunately, we could not demonstrate an independent prognostic factor for each TNM
stage. However, stage I may be too early to show the differences in protein expression levels
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of various cell-to-cell adhesion molecules or differentiation markers, while stage IV in the
current UICC/AJCC TNM staging system is already too advanced and incurable to reflect a
prognostic difference.[19] According to the current treatment strategies, stage II/III are
curable advanced stages which are continuously being investigated and challenged.
Therefore, compared with stage I or IV, an independent prognostic factor in advanced stage
II/III can offer much more important clinical value.
In conclusion, the loss of the combined expression of metaplasia biomarkers including
CDH17, MUC13m, REG4, and LGALS4, is an independent prognostic indicator in the
undifferentiated type gastric cancer and stage II/III gastric cancer.
Acknowledgments
This study was supported by funding to HJL from the SNUH Research Fund (grant number 05-2009-002), and
funding to JRG from NIH RO1 DK071590, RO1 DK071590-S1 and a VA Merit Review Award.
References
1. Van De Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, et al. A
gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;
347:1999–2009. [PubMed: 12490681]
2. Beer DG, Kardia SLR, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, et al. Gene-
expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002; 8:816–
24. [PubMed: 12118244]
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, et al. The use
of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N
Engl J Med. 2002; 346:1937–47. [PubMed: 12075054]
4. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, et al. Gene expression
profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol. 2004;
22:1564–71. [PubMed: 15051756]
5. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, et al. Use of a cDNA
microarray to analyse gene expression patterns in human cancer. Nat Genet. 1996; 14:457–60.
[PubMed: 8944026]
6. Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized
pathology archives for high-throughput in situ studies. J Pathol. 2001; 195:72–9. [PubMed:
11568893]
7. Lee HS, Cho SB, Lee HE, Kim MA, Kim JH, Park DJ, Yang HK, et al. Protein Expression Profiling
and Molecular Classification of Gastric Cancer by the Tissue Array Method. Clin Cancer Res. 2007;
13:4154–63. [PubMed: 17634543]
8. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer
through serial analysis of gene expression and its clinical implications. Cancer Sci. 2004; 95:385–
92. [PubMed: 15132764]
9. Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, Anami K, et al. Serum
olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for
gastric cancer patients. Int J Cancer. 2009; 125:2383–92. [PubMed: 19670418]
10. Nam KT, Lee HJ, Mok H, Romero-Gallo J, Crowe JE Jr, Peek RM Jr, Goldenring JR.
Amphiregulin-deficient mice develop spasmolytic polypeptide expressing metaplasia and
intestinal metaplasia. Gastroenterology. 2009; 136:1288–96. [PubMed: 19230855]
11. Lee HJ, Nam KT, Park HS, Kim MA, LaFleur BJ, Aburatani H, Yang HK, et al. Gene Expression
Profiling of Metaplastic Lineages Identifies CDH17 as a Prognostic Marker in Early Stage Gastric
Cancer. Gastroenterology. 2010; 139:213–25. [PubMed: 20398667]
12. Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, Mills JC, et al. A molecular
signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology.
2008; 134:511–22. [PubMed: 18242217]
Suh et al. Page 6
Ann Surg Oncol. Author manuscript; available in PMC 2014 January 08.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
13. Zheng H, Xu X, Miao YU, Takahashi H, Masuda S, Takano Y. The role of Reg IV gene and its
encoding product in gastric carcinogenesis. Hum Pathol. 2010; 41:59–69. [PubMed: 19740514]
14. Nakamura T, Yao T, Kabashima A, Nishiyama K, Maehara Y, Tsuneyoshi M. Loss of phenotypic
expression is related to tumour progression in early gastric differentiated adenocarcinoma.
Histopathology. 2005; 47:357–67. [PubMed: 16178890]
15. Kuniyasu H, Oue N, Sasahira T, Yi L, Moriwaka Y, Shimomoto T, Fujii K, et al. Reg IV enhances
peritoneal metastasis in gastric carcinomas. Cell Prolif. 2009; 42:110–21. [PubMed: 19143768]
16. Tahara E. Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol. 1993;
119:265–72. [PubMed: 8440743]
17. Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, Kodama T, et al. Differential
gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to
peritoneum or lymph nodes. Cancer Res. 2001; 61:889–95. [PubMed: 11221876]
18. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma-2nd English
Edition. Gastric Cancer. 1998; 1:10–24. [PubMed: 11957040]
19. Edge, SB.; Byrd, DR.; Compton, CC. AJCC cancer staging manual. 7th ed.. NY Springer; New
York: 2009.
20. Yamamoto E, Suzuki H, Takamaru H, Yamamoto H, Toyota M, Shinomura Y. Role of DNA
Methylation in the Development of Diffuse-Type Gastric Cancer. Digestion. 2011; 83:241–9.
[PubMed: 21273772]
21. Tamura G, Sato K, Akiyama S, Tsuchiya T, Endoh Y, Usuba O, Kimura W, et al. Molecular
characterization of undifferentiated-type gastric carcinoma. Lab Invest. 2001; 81:593–8. [PubMed:
11304579]
22. Saito A, Shimoda T, Nakanishi Y, Ochiai A, Toda G. Histologic heterogeneity and mucin
phenotypic expression in early gastric cancer. Pathol Int. 2001; 51:165–71. [PubMed: 11328531]
23. Ikeda Y, Mori M, Kamakura T, Haraguchi Y, Saku M, Sugimachi K. Increased incidence of
undifferentiated type of gastric cancer with tumor progression in 912 patients with early gastric
cancer and 1245 with advanced gastric cancer. Cancer. 1994; 73:2459–63. [PubMed: 8174042]
24. Gessner R, Tauber R. Intestinal Cell Adhesion Molecules: Liver Intestine Cadherin. Ann N Y
Acad Sci. 2000; 915:136–43. [PubMed: 11193569]
25. Williams SJ, Wreschner DH, Tran M, Eyre HJ, Sutherland GR, McGuckin MA. Muc13, a novel
human cell surface mucin expressed by epithelial and hemopoietic cells. J Biol Chem. 2001;
276:18327–36. [PubMed: 11278439]
26. Shimamura T, Ito H, Shibahara J, Watanabe A, Hippo Y, Taniguchi H, Chen Y, et al.
Overexpression of MUC13 is associated with intestinal-type gastric cancer. Cancer Sci. 2005;
96:265–73. [PubMed: 15904467]
27. Demetter P, Nagy N, Martin B, Mathieu A, Dumont P, Decaestecker C, Salmon I. The galectin
family and digestive disease. J Pathol. 2008; 215:1–12. [PubMed: 18335458]
28. Huflejt ME, Leffler H. Galectin-4 in normal tissues and cancer. Glycoconj J. 2004; 20:247–55.
[PubMed: 15115909]
29. Balan V, Nangia-Makker P, Raz A. Galectins as Cancer Biomarkers. Cancers. 2010; 2:592–610.
[PubMed: 23658855]
30. Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y, Okamoto H. A novel
gene activated in regenerating islets. J Biol Chem. 1988; 263:2111–4. [PubMed: 2963000]
31. Yamagishi H, Fukui H, Sekikawa A, Kono T, Fujii S, Ichikawa K, Tomita S, et al. Expression
profile of REG family proteins REG Iα and REG IV in advanced gastric cancer: comparison with
mucin phenotype and prognostic markers. Mod Pathol. 2009; 22:906–13. [PubMed: 19329938]
32. Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, Noguchi T, et al. Expression
and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is
associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol.
2005; 207:185–98. [PubMed: 16086444]
33. Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, Tanaka S, et al. Reg IV is a serum
biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy.
Oncogene. 2007; 26:4383–93. [PubMed: 17237819]
Suh et al. Page 7
Ann Surg Oncol. Author manuscript; available in PMC 2014 January 08.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
34. Eidelman S, Damsky CH, Wheelock MJ, Damjanov I. Expression of the cell-cell adhesion
glycoprotein cell-CAM 120/80 in normal human tissues and tumors. Am J Pathol. 1989; 135:101–
10. [PubMed: 2774055]
35. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J
Pathol. 1998; 1:333–9. [PubMed: 9708792]
36. Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W, et al. E-
cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with
cellular dedifferentiation and glandular disintegration. Cancer Res. 1993; 53:1690–5. [PubMed:
8453643]
37. Mayer B, Jauch KW, Schildberg FW, Funke I, Gunthert U, Figdor CG, Johnson JP. De-novo
expression of CD44 and survival in gastric cancer. Lancet. 1993; 342:1019–22. [PubMed:
7692200]
38. Brackenbury R. Molecular mechanisms of cell adhesion in normal and transformed cells. Cancer
Metastasis Rev. 1985; 4:41–58. [PubMed: 3888382]
39. Shimada Y, Yamasaki S, Hashimoto Y, Ito T, Kawamura J, Soma T, Ino Y, et al. Clinical
significance of dysadherin expression in gastric cancer patients. Clin Cancer Res. 2004; 10:2818–
23. [PubMed: 15102690]
40. Park JH, Lee BL, Yoon J, Kim J, Kim MA, Yang HK, Kim WH. Focal adhesion kinase (FAK)
gene amplification and its clinical implications in gastric cancer. Hum Pathol. 2010; 41:1664–73.
[PubMed: 20869748]
41. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K, Haglund C.
Epithelial and stromal syndecan 1 expression as predictor of outcome in patients with gastric
cancer. Int J Cancer. 2001; 95:1–6. [PubMed: 11241302]
42. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUC1, MUC2, MUC5AC, and MUC6
expressions in gastric carcinomas. Cancer. 2001; 92:1427–34. [PubMed: 11745219]
43. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates
with gastric cancer prognosis. J Pathol. 2003; 200:39–46. [PubMed: 12692839]
Suh et al. Page 8
Ann Surg Oncol. Author manuscript; available in PMC 2014 January 08.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Synopsis
Immunohistochemical staining using tissue microarrays indicates that the combined loss
of expression of MUC13, CDH17, LGALS4 and REG4 is an independent prognostic
indicator in undifferentiated or stage II/III gastric cancer.
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Figure 1.
Protein expression using immunohistochemical staining (100x). membranous type MUC13;
MUC13m (1a), cytoplasmic type MUC13; MUC13c (1b), CDH17 (1c), LGALS4 (1d),
REG4 (1e), OLFM4 (1f), MUC5AC (1g) and KRT20 (1h).
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Figure 2.
Univariate survival analysis of membranous type MUC13; MUC13m (2a), cytoplasmic type
MUC13;MUC13c (2b), CDH17 (2c), LGALS4 (2d), REG4 (2e), OLFM4 (2f), MUC5AC
(2g) and KRT20 (2h).
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Figure 3.
Survival curves for the combined expression of membranous type MUC13, CDH17,
LGALS4, REG4 (3a) and the combination of the positive expression (Group A) and
expression loss (Group B) groups (3b). Group A indicates the positive expression group in
which ≥ 3 proteins among membranous type MUC13, CDH17, LGALS4 and REG4 were
expressed. Group B indicates the expression loss group in which ≤ 2 proteins among
membranous type MUC13, CDH17, LGALS4 and REG4 were expressed.
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Figure 4.
Survival curves between groups A and B in undifferentiated gastric cancer (4a), AGC (4b),
and N+ cancer (4c). Group A indicates the positive expression group in which ≥ 3 proteins
among membranous type MUC13m, CDH17, LGALS4 and REG4 were expressed. Group B
indicates the expression loss group in which ≤ 2 proteins among membranous type MUC13,
CDH17, LGALS4 and REG4 were expressed. AGC indicates gastric cancer with ≥ T2 stage.
N+ indicates gastric cancer with ≥ N1 stage.
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Figure 5.
Survival curves between groups A and B in stages I (5a), II/III (5b) and IV (5c). Group A
indicates the positive expression group in which ≥ 3 proteins among membranous type
MUC13m, CDH17, LGALS4 and REG4 were expressed. Group B indicates the expression
loss group in which ≤ 2 proteins among membranous type MUC13, CDH17, LGALS4 and
REG4 were expressed.
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Table 1
A detailed description of 7 selected primary antibodies used in immunohistochemistry.
Antigen Antibody (dilution)
MUC13 Mouse IgG1 (1/500)
CDH17 Mouse IgG1 (1/250)
OLFM4 Rabbit polyclonal (1/200)
KRT20 Mouse IgG2a (Prediluted)
LGLAS4 Mouse IgG1 (1/50)
MUC5AC Mouse IgG1 (1/100)
REG4 Goat polyclonal (1/100)
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Table 2
Patients’ demographic data of SNUH-2004-GC for tissue microarrays.
SNUH-2004-GC n=450
Age (yr) 57.5±12.7
Male to Female ratio 2.7 :1
Location Upper 83 (18.4%)
Mid 126 (28.0%)
Lower 220 (48.9%)
Entire 20 (4.4%)
Remnant 1 (0.2%)
WHO Papillary 2 (0.4%)
Well differentiated 30 (6.7%)
Moderately differentiated 155 (34.4%)
Poorly differentiated 159 (35.3%)
Mucinous 14 (3.1%)
Signet Ring cell 82 (18.2%)
Undetermined 8 (1.8%)
Lauren Intestinal 185 (41.1%)
Diffuse 185 (41.1%)
Mixed 77 (17.1%)
Undetermined 3 (0.7%)
Lymphatic invasion 262 (58.2%)
Venous invasion 77 (17.1%)
Perineural invasion 217 (48.2%)
Size (cm) 5.6±3.1
metastatic LN 5.6±8.7
Retrieved LN 31.4±12.9
Radicality R0 403 (89.6%)
R1/R2 47 (10.4%)
T stage T1 128 (28.4%)
T2 71 (15.8%)
T3 155 (34.4%)
T4 96 (21.3%)
N stage N0 192 (42.7%)
N1 63 (14.0%)
N2 60 (13.3%)
N3 135 (30.0%)
M stage M0 397 (88.2%)
M1 53 (11.8%)
TNM stage Stage I 157 (34.9%)
Stage II 102 (22.7%)
Stage III 138 (30.7%)
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SNUH-2004-GC n=450
Stage IV 53 (11.8%)
F/U month (mo) 49 (0-64)
SNUH-2004-GC indicates the collection of 450 gastric adenocarcinomas resected at Seoul National University Hospital in 2004 (SuperBioChips)
used for tissue microarrays.
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Table 4
Clinicopathologic characteristics between Groups A and B
Group A (n=164) Group B (n=229) P value
Age 59.9±12.1 56.5±13.0 0.009
Sex Male:Female 2.5:1 (117/47) 2.6:1 (166/63) 0.820
Differentiation Differentiated 90 (54.9%) 73 (31.9%) <0.001
Undifferentiated 74 (45.1%) 148 (64.6%)
Unknown 0 8 (3.5%)
Lauren Intestinal 91 (55.5%) 74 (32.3%) <0.001
Diffuse 53 (32.3%) 107 (46.7%)
Mixed 20 (12.2%) 45 (19.7%)
Unknown 0 3 (1.3%)
Lymphatic invasion Invasion (+) 90 (54.9%) 152 (66.4%) 0.027
Invasion (−) 74 (45.1%) 77 (33.6%)
Venous invasion Invasion (+) 28 (17.1%) 44 (19.2%) 0.692
Invasion (−) 136 (82.9%) 185 (80.8%)
Perineural invasion Invasion (+) 65 (39.6%) 13 (58.1%) <0.001
Invasion (−) 99 (60.4%) 96 (41.9%)
Size (cm) 5.1±2.4 6.1±3.5 0.001
Metastatic LN 4.5±8.2 6.8±9.2 0.008
Retrieved LN 31.1±13.0 31.7±12.9 0.635
Radicality R0 153 (93.3%) 196 (85.6%) 0.022
R1/R2 11 (6.7%) 33 (14.4%)
T stage T1 54 (32.9%) 43 (18.8%) 0.008
T2 25 (15.2%) 39 (17.0%)
T3 56 (34.1%) 85 (37.1%)
T4 29 (17.7%) 62 (27.1%)
N stage N0 76 (46.3%) 79 (34.5%) 0.003
N1 26 (15.9%) 32 (14.0%)
N2 28 (17.1%) 30 (13.1%)
N3 34 (20.7%) 88 (38.4%)
M stage M0 151 (92.1%) 192 (83.8%) 0.016
M1 13 (7.9%) 37 (16.2%)
TNM stage Stage I 64 (39.0%) 60 (26.2%) 0.009
Stage II 40 (24.4%) 51 (22.3%)
Stage III 47 (28.7%) 81 (35.4%)
Stage IV 13 (7.9%) 37 (16.2%)
Group A indicates the positive expression group in which ≥ 3 proteins among membranous type MUC13m, CDH17, LGALS4 and REG4 were
expressed. Group B indicates the expression loss group in which ≤ 2 proteins among membranous type MUC13, CDH17, LGALS4 and REG4
were expressed.
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Table 5
Cox multivariate analysis for disease-specific survival in gastric cancer subgroups.
Subgroups Prognostic factor Univariate Multivariate Hazard Ratio (95.0% CI)
Undifferentiated cancer TNM stage (stage I) <0.001 <0.001
    stage II 0.093 3.952 (0.797-19.602)
    stage III <0.001 22.756 (5.045-102.636)
    stage IV <0.001 66.992 (13.865-323.682)
Lymphatic invasion <0.001 0.695 1.138 (0.596-2.176)
Venous invasion <0.001 0.551 1.168 (0.7-1.949)
Perineural invasion <0.001 0.450 0.799 (0.447-1.43)
Protein expression (expression/loss) 0.002 0.020 1.927 (1.11-3.345)
AGC N stage (N0) <0.001 <0.001
        N1 0.120 2.273 (0.808-6.389)
        N2 <0.001 5.390 (2.156-13.474)
        N3 <0.001 11.861 (5.11-27.527)
Differentiation 0.030 0.129 1.355 (0.915-2.005)
Lymphatic invasion <0.001 0.471 0.816 (0.469-1.419)
Venous invasion <0.001 0.014 1.617 (1.102-2.372)
Perineural invasion <0.001 0.330 1.242 (0.803-1.922)
Protein expression (expression/loss) 0.004 0.019 1.625 (1.084-2.437)
N+ cancer T stage (T1) <0.001 <0.001
        T2 0.777 1.415 (0.128-15.624)
        T3 0.017 11.136 (1.539-80.597)
        T4 0.004 18.573 (2.569-134.283)
Differentiation 0.034 0.151 1.342 (0.898-2.004)
Lymphatic invasion 0.023 0.781 1.085 (0.609-1.934)
Venous invasion <0.001 0.006 1.714 (1.171-2.509)
Perineural invasion <0.001 0.469 0.833 (0.507-1.367)
Protein expression (expression/loss) 0.012 0.023 1.602 (1.068-2.402)
Stage II /III Age(≤70 vs. >70 yr) 0.019 0.050 1.646 (0.999-2.712)
TNM stage (stage II vs. III) <0.001 <0.001 6.416 (3.181-12.941)
Venous invasion <0.001 0.041 1.683 (1.021-2.773)
Protein expression (expression/loss) 0.021 0.010 1.916 (1.166-3.149)
AGC indicates gastric cancer with ≥ T2 stage. N+ indicates gastric cancer with ≥ N1 stage.
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